GlobeNewswire: NeoTherma Oncology Contains the last 10 of 5 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:09:46ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/01/09/1968470/0/en/NeoTherma-Oncology-Announces-FDA-IDE-Submission-to-Permit-Investigational-Treatment-of-Pancreatic-Cancer-Patients-with-Its-FDA-Designated-Breakthrough-Device-the-VectRx-Thermal-Onc.html?f=22&fvtc=4&fvtv=32510NeoTherma Oncology Announces FDA IDE Submission to Permit Investigational Treatment of Pancreatic Cancer Patients with Its FDA-Designated Breakthrough Device, the VectRx™ Thermal Oncology System2020-01-09T14:00:00Z<![CDATA[WICHITA, Kan., Jan. 09, 2020 (GLOBE NEWSWIRE) -- NeoTherma Oncology (NTO), a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces they have submitted an Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) to initiate First-in-Human (FiH) studies of the VectRx™ System in patients with pancreatic cancer being treated with standard of care chemotherapy under the Early Feasibility Study (EFS) Guidance. Previously granted ‘Breakthrough Technology’ designation by the FDA, company CEO Dr. Michael Wandell stated, “device development and preclinical work have advanced to the point that we are prepared to move forward upon FDA approval to begin the clinical studies of the VectRx™ System investigational device.”]]>https://www.globenewswire.com/news-release/2018/08/21/1554729/0/en/NeoTherma-Oncology-Receives-NCI-Grant-to-Advance-VectRx-MRI-Thermometry.html?f=22&fvtc=4&fvtv=32510NeoTherma Oncology Receives NCI Grant to Advance VectRx™ MRI Thermometry2018-08-21T16:00:00Z<![CDATA[WICHITA, Kan., Aug. 21, 2018 (GLOBE NEWSWIRE) -- NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the Company was recently awarded Small Business Innovation Research grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This Phase I award provides resources to enable ‘Quantifiable Thermal Therapy Using Magnetic Resonance Thermometry Imaging’. Under terms of the grant, NTO will work closely with researchers from the Department of Radiology and Imaging Science, Utah Center for Advanced Imaging and Research at the University of Utah School of Medicine.]]>https://www.globenewswire.com/news-release/2018/08/14/1551875/0/en/NeoTherma-Oncology-Raises-6-Million-to-Advance-VectRx-to-Human-Testing.html?f=22&fvtc=4&fvtv=32510NeoTherma Oncology Raises $6 Million to Advance VectRx™ to Human Testing2018-08-14T19:04:45Z<![CDATA[WICHITA, Kan., Aug. 14, 2018 (GLOBE NEWSWIRE) -- NeoTherma Oncology (NTO), developer of an advanced bioelectric medical device for noninvasive treatment of serious cancers, today announced the closing of a $6 million capital raise. The financing provides the resources to conduct human testing of NTO’s VectRx™ thermal oncology treatment platform, designated by FDA as a ‘Breakthrough Therapy’ for Pancreatic Cancer, expediting patient access to this novel adjuvant therapy[1]. The Series A convertible note raise was co-led by a current investor, Gary Barnett, along with new investment groups, Flor-Med Partners, LLC and R & K Edwards Investments, LLC, and others.]]>https://www.globenewswire.com/news-release/2017/05/10/982120/0/en/NeoTherma-Oncology-Reports-on-the-Safety-and-Effectiveness-of-RF-generated-Heat-Delivery-in-Preclinical-Animal-Studies-with-the-Vectron-TTx-Thermal-Device-intended-for-Treatment-of.html?f=22&fvtc=4&fvtv=32510NeoTherma Oncology Reports on the Safety and Effectiveness of RF-generated Heat Delivery in Preclinical Animal Studies with the Vectron TTx Thermal Device intended for Treatment of Deep Solid Tumors at Society for Thermal Medicine Annual Meeting2017-05-10T20:33:30Z<![CDATA[WICHITA, Kan., May 10, 2017 (GLOBE NEWSWIRE) -- NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, reported the results of a pre-clinical porcine study that demonstrated the safe and effective heating of the pancreas with a prototype version of its Vectron TTx device.]]>https://www.globenewswire.com/news-release/2017/04/04/954184/0/en/NeoTherma-Oncology-Announces-FDA-Granted-Its-Vectron-Thermal-Device-for-Treatment-of-Pancreatic-Cancer-Breakthrough-Device-Designation-within-Expedited-Access-Pathway.html?f=22&fvtc=4&fvtv=32510NeoTherma Oncology Announces FDA Granted Its Vectron Thermal Device for Treatment of Pancreatic Cancer Breakthrough Device Designation within Expedited Access Pathway2017-04-04T14:06:00Z<![CDATA[WICHITA, Kan., April 04, 2017 (GLOBE NEWSWIRE) -- NeoTherma Oncology, (NTO) a privately held medical device company developing novel non-invasive treatments for solid tumors, today announces that the United States Food and Drug Administration (FDA) has granted the company’s petition to admit its Vectron TTx treatment for Pancreatic Cancer as Breakthrough Device under FDA’s Expedited Access Pathway (EAP).]]>